R&D Roundup: Pharma gets in on the biotech boomSome good news for the UK industry in turbulent times is always welcome, and several announcement this month Share XR&D Roundup: Pharma gets in on the biotech boomhttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-pharma-gets-in-on-the-biotech-boom/
Roche insists Spark deal is still on, despite lacklustre take-upShareholders in Spark Therapeutics haven’t been queueing up to take advantage of Roche’s $114.50-per-share offer, forcing an extension Share XRoche insists Spark deal is still on, despite lacklustre take-uphttps://pharmaphorum.com/news/roche-insists-spark-deal-still-on-despite-lacklustre-take-up/
MS drug market heats up as FDA backs Novartis’ new pillThe FDA has approved Novartis’ Mayzent (siponimod) multiple sclerosis pill for relapsing forms of the disease, dealing a Share XMS drug market heats up as FDA backs Novartis’ new pillhttps://pharmaphorum.com/news/ms-drug-market-heats-up-as-fda-backs-novartis-new-pill/
Question marks over AbbVie/Roche’s venetoclax after safety scareAbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a Share XQuestion marks over AbbVie/Roche’s venetoclax after safety scarehttps://pharmaphorum.com/news/question-marks-over-abbvie-roches-venetoclax-after-aml-safety-scare/
Roche’s Tecentriq gains new US lung cancer indicationRoche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it Share XRoche’s Tecentriq gains new US lung cancer indicationhttps://pharmaphorum.com/news/roches-tecentriq-gains-new-us-lung-cancer-indication/
EU expands use of Roche’s new haemophilia A drugThe European Commission has approved Roche haemophilia A drug Hemlibra for patients without factor VIII inhibitors, expanding the Share XEU expands use of Roche’s new haemophilia A drughttps://pharmaphorum.com/news/eu-expands-use-of-roches-new-haemophilia-a-drug/
UK gets early access to Roche’s breast cancer immunotherapyHard on the heels of an FDA approval for Roche’s Tecentriq and Celgene’s Abraxane for triple-negative breast cancer Share XUK gets early access to Roche’s breast cancer immunotherapyhttps://pharmaphorum.com/news/uk-early-access-roches-breast-cancer-immunotherapy/
Roche gets first checkpoint inhibitor OK in breast cancerRoche’s Tecentriq was the third PD-1/PD-L1 inhibitor to reach the market but is the first in class to Share XRoche gets first checkpoint inhibitor OK in breast cancerhttps://pharmaphorum.com/news/roche-gets-first-checkpoint-inhibitor-ok-in-breast-cancer/
AbbVie/Roche seek first-line CLL use for Venclexta comboAbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new Share XAbbVie/Roche seek first-line CLL use for Venclexta combohttps://pharmaphorum.com/news/abbvie-roche-seek-first-line-cll-use-for-venclexta-combo/
